Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

377 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum kidney injury molecule 1 and β2-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes.
Colombo M, Looker HC, Farran B, Hess S, Groop L, Palmer CNA, Brosnan MJ, Dalton RN, Wong M, Turner C, Ahlqvist E, Dunger D, Agakov F, Durrington P, Livingstone S, Betteridge J, McKeigue PM, Colhoun HM; SUMMIT Investigators. Colombo M, et al. Among authors: durrington p. Diabetologia. 2019 Jan;62(1):156-168. doi: 10.1007/s00125-018-4741-9. Epub 2018 Oct 5. Diabetologia. 2019. PMID: 30288572 Free PMC article.
Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH; CARDS Investigators. Colhoun HM, et al. Am J Kidney Dis. 2009 Nov;54(5):810-9. doi: 10.1053/j.ajkd.2009.03.022. Epub 2009 Jun 21. Am J Kidney Dis. 2009. PMID: 19540640 Clinical Trial.
Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes.
Colombo M, Looker HC, Farran B, Agakov F, Brosnan MJ, Welsh P, Sattar N, Livingstone S, Durrington PN, Betteridge DJ, McKeigue PM, Colhoun HM. Colombo M, et al. Among authors: durrington pn. Atherosclerosis. 2018 Jul;274:182-190. doi: 10.1016/j.atherosclerosis.2018.05.014. Epub 2018 May 25. Atherosclerosis. 2018. PMID: 29793175 Free article.
A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts.
van Leeuwen N, Nijpels G, Becker ML, Deshmukh H, Zhou K, Stricker BH, Uitterlinden AG, Hofman A, van 't Riet E, Palmer CN, Guigas B, Slagboom PE, Durrington P, Calle RA, Neil A, Hitman G, Livingstone SJ, Colhoun H, Holman RR, McCarthy MI, Dekker JM, 't Hart LM, Pearson ER. van Leeuwen N, et al. Among authors: durrington p. Diabetologia. 2012 Jul;55(7):1971-7. doi: 10.1007/s00125-012-2537-x. Epub 2012 Mar 28. Diabetologia. 2012. PMID: 22453232 Free PMC article.
Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial.
Soedamah-Muthu SS, Livingstone SJ, Charlton-Menys V, Betteridge DJ, Hitman GA, Neil HA, Bao W, DeMicco DA, Preston GM, Fuller JH, Stehouwer CD, Schalkwijk CG, Durrington PN, Colhoun HM; CARDS Investigators. Soedamah-Muthu SS, et al. Diabetologia. 2015 Jul;58(7):1494-502. doi: 10.1007/s00125-015-3586-8. Epub 2015 Apr 22. Diabetologia. 2015. PMID: 25899452 Free PMC article. Clinical Trial.
Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial.
Colhoun HM, Betteridge DJ, Durrington P, Hitman G, Neil A, Livingstone S, Charlton-Menys V, Bao W, Demicco DA, Preston GM, Deshmukh H, Tan K, Fuller JH. Colhoun HM, et al. Among authors: durrington p. Diabetes. 2011 Sep;60(9):2379-85. doi: 10.2337/db11-0291. Epub 2011 Jul 19. Diabetes. 2011. PMID: 21771973 Free PMC article.
Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).
Raikou M, McGuire A, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, Fuller JH; CARDS Investigators. Raikou M, et al. Among authors: durrington pn. Diabetologia. 2007 Apr;50(4):733-40. doi: 10.1007/s00125-006-0561-4. Epub 2007 Jan 31. Diabetologia. 2007. PMID: 17265034
Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, DeMicco DA, Durrington PN. Charlton-Menys V, et al. Among authors: durrington pn. Diabetologia. 2009 Feb;52(2):218-25. doi: 10.1007/s00125-008-1176-8. Epub 2008 Oct 30. Diabetologia. 2009. PMID: 18972097 Clinical Trial.
377 results